Cargando…
Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice
Bleomycin (BLM) is an effective curative option in the management of several malignancies including pleural effusions; but pulmonary toxicity, comprising of pneumonitis and fibrosis, poses challenge in its use as a front-line chemotherapeutic. Although Amifostine has been found to protect lungs from...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928292/ https://www.ncbi.nlm.nih.gov/pubmed/29740320 http://dx.doi.org/10.3389/fphar.2018.00394 |
_version_ | 1783319213555843072 |
---|---|
author | Arora, Aastha Bhuria, Vikas Hazari, Puja P. Pathak, Uma Mathur, Sweta Roy, Bal G. Sandhir, Rajat Soni, Ravi Dwarakanath, Bilikere S. Bhatt, Anant N. |
author_facet | Arora, Aastha Bhuria, Vikas Hazari, Puja P. Pathak, Uma Mathur, Sweta Roy, Bal G. Sandhir, Rajat Soni, Ravi Dwarakanath, Bilikere S. Bhatt, Anant N. |
author_sort | Arora, Aastha |
collection | PubMed |
description | Bleomycin (BLM) is an effective curative option in the management of several malignancies including pleural effusions; but pulmonary toxicity, comprising of pneumonitis and fibrosis, poses challenge in its use as a front-line chemotherapeutic. Although Amifostine has been found to protect lungs from the toxic effects of radiation and BLM, its application is limited due to associated toxicity and unfavorable route of administration. Therefore, there is a need for selective, potent, and safe anti-fibrotic drugs. The current study was undertaken to assess the protective effects of DRDE-30, an analog of Amifostine, on BLM-induced lung injury in C57BL/6 mice. Whole body micro- computed tomography (CT) was used to non-invasively observe tissue damage, while broncheo-alveolar lavage fluid (BALF) and lung tissues were assessed for oxidative damage, inflammation and fibrosis. Changes in the lung density revealed by micro-CT suggested protection against BLM-induced lung injury by DRDE-30, which correlated well with changes in lung morphology and histopathology. DRDE-30 significantly blunted BLM-induced oxidative stress, inflammation and fibrosis in the lungs evidenced by reduced oxidative damage, endothelial barrier dysfunction, Myeloperoxidase (MPO) activity, pro-inflammatory cytokine release and protection of tissue architecture, that could be linked to enhanced anti-oxidant defense system and suppression of redox-sensitive pro-inflammatory signaling cascades. DRDE-30 decreased the BLM-induced augmentation in BALF TGF-β and lung hydroxyproline levels, as well as reduced the expression of the mesenchymal marker α-smooth muscle actin (α-SMA), suggesting the suppression of epithelial to mesenchymal transition (EMT) as one of its anti-fibrotic effects. The results demonstrate that the Amifostine analog, DRDE-30, ameliorates the oxidative injury and lung fibrosis induced by BLM and strengthen its potential use as an adjuvant in alleviating the side effects of BLM. |
format | Online Article Text |
id | pubmed-5928292 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59282922018-05-08 Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice Arora, Aastha Bhuria, Vikas Hazari, Puja P. Pathak, Uma Mathur, Sweta Roy, Bal G. Sandhir, Rajat Soni, Ravi Dwarakanath, Bilikere S. Bhatt, Anant N. Front Pharmacol Pharmacology Bleomycin (BLM) is an effective curative option in the management of several malignancies including pleural effusions; but pulmonary toxicity, comprising of pneumonitis and fibrosis, poses challenge in its use as a front-line chemotherapeutic. Although Amifostine has been found to protect lungs from the toxic effects of radiation and BLM, its application is limited due to associated toxicity and unfavorable route of administration. Therefore, there is a need for selective, potent, and safe anti-fibrotic drugs. The current study was undertaken to assess the protective effects of DRDE-30, an analog of Amifostine, on BLM-induced lung injury in C57BL/6 mice. Whole body micro- computed tomography (CT) was used to non-invasively observe tissue damage, while broncheo-alveolar lavage fluid (BALF) and lung tissues were assessed for oxidative damage, inflammation and fibrosis. Changes in the lung density revealed by micro-CT suggested protection against BLM-induced lung injury by DRDE-30, which correlated well with changes in lung morphology and histopathology. DRDE-30 significantly blunted BLM-induced oxidative stress, inflammation and fibrosis in the lungs evidenced by reduced oxidative damage, endothelial barrier dysfunction, Myeloperoxidase (MPO) activity, pro-inflammatory cytokine release and protection of tissue architecture, that could be linked to enhanced anti-oxidant defense system and suppression of redox-sensitive pro-inflammatory signaling cascades. DRDE-30 decreased the BLM-induced augmentation in BALF TGF-β and lung hydroxyproline levels, as well as reduced the expression of the mesenchymal marker α-smooth muscle actin (α-SMA), suggesting the suppression of epithelial to mesenchymal transition (EMT) as one of its anti-fibrotic effects. The results demonstrate that the Amifostine analog, DRDE-30, ameliorates the oxidative injury and lung fibrosis induced by BLM and strengthen its potential use as an adjuvant in alleviating the side effects of BLM. Frontiers Media S.A. 2018-04-24 /pmc/articles/PMC5928292/ /pubmed/29740320 http://dx.doi.org/10.3389/fphar.2018.00394 Text en Copyright © 2018 Arora, Bhuria, Hazari, Pathak, Mathur, Roy, Sandhir, Soni, Dwarakanath and Bhatt. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Arora, Aastha Bhuria, Vikas Hazari, Puja P. Pathak, Uma Mathur, Sweta Roy, Bal G. Sandhir, Rajat Soni, Ravi Dwarakanath, Bilikere S. Bhatt, Anant N. Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice |
title | Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice |
title_full | Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice |
title_fullStr | Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice |
title_full_unstemmed | Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice |
title_short | Amifostine Analog, DRDE-30, Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice |
title_sort | amifostine analog, drde-30, attenuates bleomycin-induced pulmonary fibrosis in mice |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928292/ https://www.ncbi.nlm.nih.gov/pubmed/29740320 http://dx.doi.org/10.3389/fphar.2018.00394 |
work_keys_str_mv | AT aroraaastha amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice AT bhuriavikas amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice AT hazaripujap amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice AT pathakuma amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice AT mathursweta amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice AT roybalg amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice AT sandhirrajat amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice AT soniravi amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice AT dwarakanathbilikeres amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice AT bhattanantn amifostineanalogdrde30attenuatesbleomycininducedpulmonaryfibrosisinmice |